Ustekinumab for Active Sight-Threatening Uveitis

NCT01647152 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Uveitis

Interventions

DRUG: Ustekinumab

Sponsor

National Eye Institute (NEI)